世界卫生组织推荐的新的较短疗程在一个耐多药结核病高负担国家的适用性。 - Suppr

Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.

作者信息

Javaid Arshad, Ahmad Nafees, Khan Amer Hayat, Shaheen Zubair

机构信息

Dept of Pulmonology, Lady Reading Hospital Peshawar, Peshawar, Pakistan.

Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia Pulau Pinang, Penang, Malaysia

出版信息

Eur Respir J. 2017 Jan 3;49(1). doi: 10.1183/13993003.01967-2016. Print 2017 Jan.

DOI:10.1183/13993003.01967-2016

PMID:28049176

Abstract

摘要

相似文献

Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.世界卫生组织推荐的新的较短疗程在一个耐多药结核病高负担国家的适用性。

Eur Respir J. 2017 Jan 3;49(1). doi: 10.1183/13993003.01967-2016. Print 2017 Jan.

Tuberculosis treatment: dangerous regimens?结核病治疗：危险的治疗方案？

Int J Tuberc Lung Dis. 2001 Jan;5(1):1-3.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.关于管理耐多药和广泛耐药结核病病例的标准化治疗方案的提案。

Eur Respir J. 2017 Jul 5;50(1). doi: 10.1183/13993003.00648-2017. Print 2017 Jul.

Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?采用2HRZE/6HE方案治疗世界卫生组织分类I型结核病是否是一种合理的做法？

Int J Tuberc Lung Dis. 1999 Sep;3(9):747-8.

Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.耐多药肺结核12个月治疗方案的结果

Int J Tuberc Lung Dis. 2002 Dec;6(12):1102-9.

[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].阿莫西林-克拉维酸与氧氟沙星联合治疗耐多药结核分枝杆菌

Kekkaku. 1997 Jan;72(1):9-13.

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.成人及儿童结核病和结核感染的治疗。美国胸科学会。

Monaldi Arch Chest Dis. 1994 Sep;49(4):327-45.

[Therapy of tuberculosis in the adult].[成人肺结核的治疗]

Med Klin (Munich). 1995 Apr 15;90(4):229-30.

[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].含吡嗪酰胺的6个月方案治疗初治肺结核患者的疗效及问题

Kekkaku. 2001 Jan;76(1):33-43.

Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.较短疗程的“孟加拉方案”在高耐多药结核病环境中的适用性。

Int J Infect Dis. 2017 Mar;56:190-193. doi: 10.1016/j.ijid.2016.10.021. Epub 2016 Nov 2.

引用本文的文献

Why do patients with DR-TB do not complete their treatment? Findings of a qualitative study from Pakistan.为什么耐多药结核病患者不完成治疗？来自巴基斯坦的定性研究结果。

BMJ Open Respir Res. 2024 Feb 26;11(1):e002186. doi: 10.1136/bmjresp-2023-002186.

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country.在一个高负担国家，个体化较长疗程与标准化较短疗程治疗耐多药结核病的比较效果

Front Pharmacol. 2022 Sep 6;13:973713. doi: 10.3389/fphar.2022.973713. eCollection 2022.

Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: a multicentre retrospective observational study.时间至痰培养转阴对预测广泛耐药结核病患者治愈的预后准确性：一项多中心回顾性观察研究。

BMC Infect Dis. 2022 Mar 2;22(1):204. doi: 10.1186/s12879-022-07202-y.

High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.巴基斯坦儿童利福平/耐多药结核病治疗成功率高：一项多中心回顾性观察分析。

BMC Infect Dis. 2021 Dec 4;21(1):1209. doi: 10.1186/s12879-021-06935-6.

Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.巴基斯坦耐多药结核病患者更短治疗方案的疗效：一项多中心回顾性病历研究。

Am J Trop Med Hyg. 2021 Mar 15;104(5):1784-1791. doi: 10.4269/ajtmh.20-1134.

Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.将耐药结核病治疗指南在饱受战争蹂躏的阿富汗坎大哈付诸实践：一项回顾性队列研究。

PLoS One. 2020 Aug 21;15(8):e0237787. doi: 10.1371/journal.pone.0237787. eCollection 2020.

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。

Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic.在孟买的一家大型私人诊所，很少有符合新推荐的短程耐多药结核病方案条件的人。

BMC Infect Dis. 2019 Jan 28;19(1):94. doi: 10.1186/s12879-019-3726-8.

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案

Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.

Tuberculosis elimination: where are we now?结核病消除：我们现在在哪里？

Eur Respir Rev. 2018 Jun 13;27(148). doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献